DMRA Damora Therapeutics, Inc.
$21.96▲ +3.29%
Healthcare
Other
After hours
$21.96▲ +0.00%
Oct 27, 4:17 PM ET
Volume 286.1K
Avg Volume (10D) 439.8K
Key Metrics & Fundamentals
Market Cap
$1.36B
P/E Ratio
–
Div Yield
0.00%
52W Range
4.95 - 38.33
% vs 50 MA
-8.96%
% vs 200 MA
-14.49%
RSI-14
52.9
MACD Histogram
+0.5500
Beta (1Y vs SPY)
3.54
Free Cash Flow
-$21.87M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$35.00M
COGS
–
Operating Exp
$34.99M
Operating Income
-$34.99M
EBIT
-$34.99M
Pretax Income
-$30.92M
Net Income
-$31.17M
EPS (Diluted)
-0.39
Price & Volume History
Loading chart…
Recent News
Damora Therapeutics (DMRA) Stock Looks Above Fair Value On Book Value
Simply Wall St. · Oct 10, 2026 10:21 AM ET
Damora Therapeutics (DMRA) Climbed, So What Is Drawing Attention Now?
Simply Wall St. · Oct 10, 2026 1:10 AM ET
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 7:59 AM ET
Damora Therapeutics Insider Bought Shares Worth $252,875, According to a Recent SEC Filing
MT Newswires · Sep 28, 2026 7:14 AM ET
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 3, 2026 8:00 AM ET
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · Aug 10, 2026 4:05 PM ET
Damora Therapeutics Begins Trial of DMR-001 in ET, Myelofibrosis
MT Newswires · Aug 5, 2026 10:42 AM ET
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis
GlobeNewswire · Aug 5, 2026 8:00 AM ET
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 3, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See DMRA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.